OKYO Pharma (OKYO) vs Pelthos Therapeutics (PTHS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Pelthos Therapeutics (PTHS) has outperformed OKYO Pharma (OKYO) over the past year, losing 24.5% versus a loss of 37.9%. Pelthos Therapeutics is the larger company by market cap ($78.5 million vs $72.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OKYO | PTHS |
|---|---|---|
| Share price | $1.39 | $20.50 |
| Market cap | $72.95M | $78.48M |
| 1-day change | -2.73% | -2.33% |
| YTD return | -32.85% | -33.87% |
| 1-year return | -37.95% | -24.47% |
| EPS (TTM) | $-0.24 | $-27.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.20 | $37.50 |
| 52-week low | $1.27 | $18.19 |
| Distance from 52-week high | -56.56% | -45.33% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +499.28% | +159.22% |
| Average volume | 94.59K | 60.07K |
| Shares outstanding | 52.48M | 3.83M |
| Employees | 5 | 92 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PTHS has outperformed OKYO by 13.5 percentage points over the past year.
About OKYO Pharma
OKYO stock →OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain.
Healthcare · Biotechnology · 5 employees
About Pelthos Therapeutics
PTHS stock →Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older.
Healthcare · Biotechnology · 92 employees
OKYO vs PTHS FAQ
Which is bigger, OKYO Pharma or Pelthos Therapeutics?
Pelthos Therapeutics (PTHS) is larger, with a market capitalization of $78.48M compared with $72.95M for OKYO Pharma (OKYO).
Which stock has performed better over the past year, OKYO or PTHS?
PTHS returned -24.47% over the past 12 months, compared with -37.95% for OKYO (price return, excluding dividends). Past performance does not predict future results.
Are OKYO Pharma and Pelthos Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.